SOURCE: Healtheuniverse, Inc.

October 13, 2006 15:38 ET

Healtheuniverse Announces Expansion of International Research and Development Center to Further Stem Cell Applications, Clinical Trials, and Product Line Commercialization

Stem Cell R & D Center and Asia Pacific Headquarters Are Being Established With the Support of the Economic Development Board of Singapore

COVINA, CA -- (MARKET WIRE) -- October 13, 2006 --Healtheuniverse, Inc. (PINKSHEETS: HLUN), a diversified biotechnology development firm specializing in the development and commercialization of patented biopharmaceutical and biomedical products announced today the incorporation of its new wholly owned subsidiary in Singapore, Healtheuniverse Pte Ltd. The Company's first international research facility will collaborate with other research and development facilities in Asia in preparation for the development of stem cell applications, clinical trials and product line commercialization. The research and development center will employ approximately 12 scientists and staff members while also functioning as the headquarters for the Asia Pacific region.

Healtheuniverse Pte Ltd., under the direction of Dr. Vipul Dev, is being established with the support from the Economic Development Board of Singapore (EDB). The Economic Development Board (EDB) is Singapore's lead agency responsible for planning and executing strategies to sustain Singapore's position as a compelling global hub for business and investment. The planned expansion is a key step in the Company's move to be the first to commercialize the use of stem cell based applications and regenerative medicine in the $15 billion worldwide plastic, reconstructive and cosmetic surgery market.


HEALTHeUNIVERSE, Inc. is a biotechnology development firm specializing in the development and commercialization of patented Biopharmaceutical and Biomedical products. We are engaged in research and development of regenerative medicine therapies using non-embryonic adult stem cells for use in plastic, reconstructive, orthopedic, vascular, and cardiac surgery. Healtheuniverse strives to be the first to commercialize the use of regenerative medicine in plastic and reconstructive surgery and to develop therapeutic uses in the most profitable commercial applications. More information on Healtheuniverse is available online at

Safe Harbor Statement

This press release contains statements, which may constitute "forward-looking statements" within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Those statements include statements regarding the intent, belief or current expectations of Healtheuniverse, Inc., and members of their management as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. Important factors currently known to management that could cause actual results to differ materially from those in forward-statements include fluctuation of operating results, the ability to compete successfully and the ability to complete before-mentioned transactions. The company undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results.

Contact Information

  • For more information, please contact:
    Healtheuniverse, Inc.
    Investor Relations
    Email Contact